Indaptus Therapeutics, Inc. Debt Conversion, Converted Instrument, Rate
Indaptus Therapeutics, Inc. (INDP) had Debt Conversion, Converted Instrument, Rate of 80.00% as of 2025-07-27, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentRate · last filed 2026-03-17
- 2025-07-27: Debt Conversion, Converted Instrument, Rate 80.00%.
- 2025-06-30: Debt Conversion, Converted Instrument, Rate 1 month 6.00%; Debt Conversion, Converted Instrument, Rate 6 month 6.00%.
| Period end | Debt Conversion, Converted Instrument, Rate | Debt Conversion, Converted Instrument, Rate 1 month | Debt Conversion, Converted Instrument, Rate 6 month |
|---|---|---|---|
| 2025-07-27 | 80.00% 10-K · filed 2026-03-17 | ||
| 2025-06-30 | 6.00% 10-K · filed 2026-03-17 | 6.00% 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |